SpringWorks Therapeutics, Inc. (SWTX) incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported a loss of $1.27 per share in the year-ago quarter.In the third quarter, total revenues were $49.3 million, which missed the Zacks Consensus Estimate of $54 million. Total revenues comprised net product sales of Ogsiveo (nirogacestat), SpringWorks’ only marketed drug. The company did not generate any reve ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participants Anupam Rama - JPMorgan Peter Lawson - Barclays Corinne Johnson - Goldman Sachs David Nierengarten - Wedbush Secur ...

STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the compan ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $1.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.26%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.12 per share when it actually produced a loss of $0.54, delivering a surprise of 51.79%.Over the last four quarters ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ FORM 10-Q ____________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-39044 _ ...

Exhibit 99.1 SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights ® – Achieved $49.3 million in OGSIVEO (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validatio ...

– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – ...

– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN – – Patients achieved deep and durable reductions in tumor volume and early, sustained and clinically meaningful improvements in pain and health-related quality of life – – New Drug and Marketing Authorization Applications under review; U.S. PDUFA action date set for February 28, 2025 – STAMFORD, Conn., Nov. 11, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeut ...

Core Insights - SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer [3] - The company will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on November 13, 2024 [1] - SpringWorks has developed OGSIVEO® (nirogacestat), the first FDA-approved therapy for adult patients with progressing desmoid tumors [3] Company Overview - SpringWorks applies a precision medicine approach to develop life-changing medicines for patients with severe rare diseases and cancer [3] - The company has a diversified pipeline targeting solid tumors and hematological cancers, with programs at various stages from preclinical to advanced clinical trials [3] - SpringWorks collaborates with industry and academic innovators to enhance its portfolio and create more solutions for patients [3] Event Information - The fireside chat will take place in Boston, Massachusetts at 1:00 p.m. ET [1] - A live webcast of the event can be accessed on the company's website, with a replay available for a limited time afterward [2]

Biotech Forum Discussion - The Biotech Forum has been dominated by discussions on lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months [1] - The forum offers real-time trading ideas and insights from seasoned biotech investors [1] SpringWorks Therapeutics Overview - SpringWorks Therapeutics Inc (NASDAQ: SWTX) is now a "commercial" stage biotech firm focused on the development of medicines [2] - The company was last analyzed in-depth in July 2023 [2] Biotech Forum Services - The Biotech Forum provides a model portfolio featuring 12-20 high upside biotech stocks [2] - The forum offers live chat for discussing trade ideas, weekly research, and option trades [2] - Market commentary and portfolio updates are provided every weekend [2] Analyst Position - The analyst holds a beneficial long position in SWTX through stock ownership, options, or other derivatives [3]